Synonyms: BIIB-068 | compound 1 [PMID: 32696648]
Compound class:
Synthetic organic
Comment: BIIB068 was designed as a novel, oral Bruton's tyrosine kinase (BTK) inhibitor and is intended for the treatment of autoimmune diseases [1]. Pharmacokinetics of BIIB068 in humans have been determined in a Phase 1 study following a single, ascending oral dose.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
BIIB068 dose-dependently inhibits BTK phosphorylation and B-cell activation, although inhibition of B-cell activation was not observed to be as robust as expected based on the level of pBTK inhibition [1]. In a DiscoverX kinome screen, BIIB068 exhibited >400-fold selectivity for BTK compared to the other kinases tested, including the structurally related Tec family kinases (BMX, ITK, TEC, TXK). |
Selectivity at enzymes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|